Neurostimulation Devices Market to Reach US$ 22.64 Billion by 2033 Driven by Rising Chronic Neurological Disorders and Advances in Implantable Neuromodulation Technologies ...

Market growth is fueled by increasing prevalence of chronic neurological conditions, rising demand for targeted pain management, and innovations in implantable and wearable neurostimulation ...

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Br…

Nexalin’s growing body of published data consistently demonstrates objective normalization of abnormal brain activity and ...
Yahoo Finance

Neurostimulation Devices Market Projected to Hit USD 16.56 Billion by 2033, Growing Due to Increasing Prevalence of Neurological and Chronic Pain Disorders – SNS Insider

Austin, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Neurostimulation Devices Market Size & Growth Analysis: As per SNS Insider, the Neurostimulation Devices Market is projected to be USD 6.95 billion in ...

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care

Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the launch of its new AI-designed ...
Everyday Health

How Does the PoNS Neurostimulation Device Help With Walking in MS?

For many people living with multiple sclerosis (MS), walking can become one of the most challenging daily tasks. As many as 3 in 4 people with MS have gait issues caused by factors like loss of muscle ...
Benzinga.com

EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value

On Wednesday, Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an ...
Becker's Spine Review

Mainstay Medical’s Reactiv8 earns coverage from BCBS North Dakota

Mainstay Medical’s Reactiv8 restorative neurostimulation device for chronic lower back pain earned favorable coverage from Blue Cross Blue Shield of North Dakota, according to a Feb. 6 news release.
MarketWatch

Neurostimulation Devices Market size is set to grow by USD 6.26 billion from 2023-2027, Rising prevalence of neurological disorders to boost the market growth, Technavio

NEW YORK, July 31, 2024 /PRNewswire/ -- The global neurostimulation devices market size is estimated to grow by USD 6.26 billion from 2023-2027, according to Technavio. The market is estimated to grow ...
Seeking Alpha

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation ...
Monthly Prescribing Reference

Modius Sleep, a Neurostimulation Device for Chronic Insomnia, Now Available

Credit: Neurovalens. Modius Sleep is an electrical vestibular nerve stimulator that sends signals to a neural pathway that connects to the hypothalamus. Modius Sleep lowered Insomnia Severity Index by ...
Seeking Alpha

Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

HOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced ...
MarketWatch

Nexalin Shares Soar After Neurostimulation Device Boosts Cognitive Performance for Alzheimer's Patients

Shares of Nexalin Technology nearly doubled after the company said its second-generation Sync neurostimulation device can improve cognitive performance and enhance brain network connectivity in ...